parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophil progenitors	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 3912

receipt 3920: FAR2 in dopamine neurons, braak

power: full sample +0.20 (p 0.418, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.30 (p 0.221, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.16 (p 0.532, n 18). could be the mix.
skeptic: leave-one-out range +0.10 to +0.31, sign flips 0; without severely affected donors +0.20 (p 0.418, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FAR2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3919: FAR2 in microglia, braak

power: full sample +0.09 (p 0.715, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.12 (p 0.640, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.10 (p 0.683, n 18). could be the mix.
skeptic: leave-one-out range -0.04 to +0.19, sign flips 4; without severely affected donors +0.09 (p 0.715, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FAR2 in microglia.

case closed: nothing better to follow up.

loading the receipts